Multiple Sclerosis
Advances in Clinical Trial Design, Treatment and Future Perspectives
Published on 26. May 1998
Book
Paperback/Softback
XVIII, 364 pages
978-1-85233-033-0 (ISBN)
Description
Multiple Sclerosis: Advances in Clinical Trial Design, Treatment and Future Perspectives is a review of therapeutic developments for a disease that is one of the major problems in current neurologic practice. Progress in this field has been rapid and there have been important developments in clinical trial design and a number of important trial results that have resulted in new treatment options for patients and physicians. Important ethical considerations that arise with new treatments are included, as is a perspective on the emergence of MS as a treatable disease. This book is for all neurologists, primary care physicians, and patients concerned about the treatment of MS. It will also be of value to clinical epidemiologists and biostatisticians with an interest in experimental therapies for chronic disease, to immunologists with an interest in autoimmune disease, to the pharmaceutical industry and to MS societies.
More details
Edition
Softcover reprint of the original 1st ed. 1996
Language
English
Place of publication
London
United Kingdom
Target group
Professional and scholarly
Research
Product notice
Paperback (trade)
Unsewn / adhesive bound
Illustrations
4 s/w Abbildungen
XVIII, 364 p. 4 illus.
Dimensions
Height: 235 mm
Width: 155 mm
Thickness: 21 mm
Weight
587 gr
ISBN-13
978-1-85233-033-0 (9781852330330)
DOI
10.1007/978-1-4471-1271-6
Schweitzer Classification
Other editions
Additional editions
Donald E. Goodkin | Richard A. Rudick
Multiple Sclerosis
Advances in Clinical Trial Design, Treatment and Future Perspectives
Book
10/1996
Springer
€85.55
Article exhausted; check different version
Content
1 Recent Advances and Future Challenges in Multiple Sclerosis Clinical Trial Design.- 2 Pathogenesis of Multiple Sclerosis: Relationship to Therapeutic Strategies.- 3 Future of Multiple Sclerosis Therapeutics: Rational Approaches Targeting Putative Pathogenic Mechanisms.- 4 Statistical and Design Considerations for Multiple Sclerosis Clinical Trials.- 5 Clinical Outcome Measures for Multiple Sclerosis.- 6 Use of Neuropsychologic Outcome Measures in Multiple Sclerosis Clinical Trials: Current Status and Strategies for Improving Multiple Sclerosis Clinical Trial Design.- 7 "Quality of Life" Assessment in Multiple Sclerosis Clinical Trials: Current Status and Strategies for Improving Multiple Sclerosis Clinical Trial Design.- 8. Magnetic Resonance Imaging: Current Status and Strategies for Improving Multiple Sclerosis Clinical Trial Design.- 9. Magnetic Resonance Imaging of Patients with Isolated Idiopathic Optic Neuritis, Brainstem Syndromes and Myelopathy.- 10 Strategies to Delay the Onset of Clinically Definite Multiple Sclerosis in Patients with Monosymptomatic Presentations of Optic Neuritis, Brainstem Syndromes or Myelopathy.- 11 Treatment of Multiple Sclerosis with Type I Interferons.- 12 Treatment of Multiple Sclerosis with Methotrexate.- 13 Treatment of Multiple Sclerosis with Copolymer 1.- 14 Treatment of Multiple Sclerosis with Cladribine.- 15 Ethical Considerations Raised by Clinical Trials.- 16 The Emergence of Multiple Sclerosis as a "Treatable" Condition: An Historical Perspective.